References
- Yoshinari T, Matsumoto M, Arakawa H, Okada H, Noguchi K, Suda H. Novel antitumor indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(beta-d-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506): induction of topoisomerase I-mediated DNA cleavage and mechanisms of cell line-selective cytotoxicity. Cancer Res 1995; 55: 1310–1315
- Denny W A. Edotecarin. IDrugs 2004; 7: 173–177
- Yamada Y, Tamura T, Yamamoto N, Shimoyama T, Ueda Y, Murakami H, et al. Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors. Cancer Chemother Pharmacol 2006; 2: 173–182
- Peck R. Phase I trial of J-107088, a novel topoisomerase I inhibitor, administered once every 21 days. Proc Am Soc Clin Oncol 2000; 19: 767, Abstract
- Lewis L, Perez R, Petros W, Matsumoto M, Natsumeda Y, Rothenberg M. A phase-1 study of the novel topoisomerase-I inhibitor J-107088 administered on a multiple-dose schedule. Proc Am Soc Clin Oncol 2000; 19, Abstract 385
- Perez R P, Hurwitz H, Nahum K, Lee J, Shiba D, Garcia M, et al. Phase II trials of J-107088, a non-camptotecin topoisomerase I inhibitor, in irinotecan naive/refractory metastatic colorectal cancer. Proc Am Soc Clin Oncol 2002; 21, Abstract 632
- Nahum K, Shiba D, Padavanija P, Garcia M, Hurwitz H, Mackintosh F, et al. Phase II efficacy and tolerability of edotecarin (J-107088) in patients with irinotecan-naive metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2003; 22: 1099, Abstract
- Hashimoto H, Chatterjee S, Berger N A. Mutagenic activity of topoisomerase I inhibitors. Clin Cancer Res 1995; 1: 369–376
- Merrouche Y, Mugneret F, Cahn J Y. Secondary acute promyelocytic leukemia following irinotecan and oxaliplatin for advanced colon cancer. Ann Oncol 2006; 17: 1025–1026
- Smith S M, Le Beau M M, Huo D, Karrison T, Sobecks R M, Anastasi J, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 2003; 102: 43–52
- Olney H J, Mitelman F, Johansson B, Mrozek K, Berger R, Rowley J D. Unique balanced chromosome abnormalities in treatment-related myelodysplastic syndromes and acute myeloid leukemia: report from an international workshop. Genes Chromosomes Cancer 2002; 33: 413–423
- Pitini V, Arrigo C, Aloi G, Righi M, Falduto M, Teti D. Myelodysplastic syndrome/acute myelogenous leukaemia after adjuvant chemotherapy with pyrimidine anti-metabolites in three patients. Haematologica 2001; 86: E30
- Philpott N J, Elebute M O, Powles R, Treleaven J G, Gore M, Dainton M G, et al. Platinum agents and secondary myeloid leukaemia: two cases treated only with platinum-based drugs. Br J Haematol 1996; 93: 884–887
- Travis L B, Holowaty E J, Bergfelt K, Lynch C F, Kohler B A, Wiklund T, et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med 1999; 340: 351–357
- Mauritzson N, Albin M, Rylander L, Billstrom R, Ahlgren T, Mikoczy Z, et al. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976 – 1993 and on 5098 unselected cases reported in the literature 1974 – 2001. Leukemia 2002; 16: 2366–2378